| Literature DB >> 30370043 |
Goonj Johri1, Gyan Chand1, Nitish Gupta1, Chaitra Sonthineni1, Anjali Mishra1, Gaurav Agarwal1, Sabaretnam Mayilvaganan1, Ashok Kumar Verma1, Saroj Kanta Mishra1.
Abstract
Scarless (in the neck) endoscopic thyroidectomy (SET) has evolved into a cosmetically preferred alternative to conventional thyroidectomy (ConT). Recently many of our patients are demanding SET; however their goitres are larger than the recommended size of 4-6 cm. Our aim was to compare the outcomes of ET for small (<6 cm) vs large (≥6 cm) goitres and determine its feasibility in such cases. This is a retrospective analysis of prospectively maintained database of patients undergoing ET. Patients were divided into 2 groups: I, small (<6 cm) and II, large goitres (≥6 cm). Their demographic and clinicopathological profiles, operation time, conversion and complication rates, and hospital stay were compared. 99 patients (101 procedures) were included: group I, 60 patients (61 procedures), and group II, 39 patients (40 procedures). Mean tumor size (± SD) was 4.4 ± 0.9 cm and 6.7 ± 1.1 cm in groups I and II, respectively. The groups were comparable with respect to demographic and clinical profile except for mean duration of goiter [30.1 ± 32.6 months (group I) vs 60.5 ± 102.4 months (group I), p = 0.03] and gland weight [21.5 ± 15.3 grams (group I) vs 62.3 ± 51.3 grams (group II), p = 0.001]. Although there was no significant difference between mean operating times, long term perioperative outcomes, and conversion rates, temporary hypocalcaemia and length of stay were longer in group II. One patient had permanent vocal cord palsy (~1%, 1/101); none had permanent hypoparathyroidism. Our results indicate that ET can be offered to a subset of patients with larger goitres desirous of SET with no significant difference in mean operation time, conversions, and long term postoperative complications in experienced hands.Entities:
Year: 2018 PMID: 30370043 PMCID: PMC6189669 DOI: 10.1155/2018/4057542
Source DB: PubMed Journal: J Thyroid Res
Figure 1Axillo-breast approach (ABA): (clockwise from top left) (a) patient with right solitary thyroid nodule, (b) patient position and port placement, (c) specimen, and (d) postoperative outcomes.
Figure 2Bilateral axillo-breast approach (BABA): (clockwise from top left) (a) patient with MNG, (b) patient position and port placement, (c) specimen, and (d) postoperative outcomes.
Figure 3(a-h) Intraoperative view of key steps during endoscopic thyroidectomy. (a) Opening of cervical fascia in midline using ultrasonic hook. (b) Lateral dissection and identification of common carotid artery; medial extent is identification of trachea (not shown in image). Thyroid lobe is rotated medially (shown by black arrow). (c) Identification of RLN and (d) inferior PTH gland (both shown by black arrows). (e) Inferior vascular pedicle secured after safeguarding RLN and PTH (Ligaclip can be used to avoid thermal injury). (f) Isthmusectomy. (g) Specimen placed in surgical glove which works as a retrieval bag. (h) Midline approximated using polyamide 2-0 suture continuous stitch.
Details of clinical presentation and demographic profile of patients.
|
|
|
|
|
|
|---|---|---|---|---|
| 1 | Mean age (years) | 33.7 ± 11.3 | 34.9 ± 12.0 | 0.61 |
|
| ||||
| 2 | Gender ratio F:M | 50:8 (6.3:1) | 32:7 (4.6:1) | 0.28 |
|
| ||||
| 3 | Mean tumor size (cm) | 4.4 ± 0.9 | 6.7 ± 1.1 | 0.001 |
| Range (cm) | 2.5-5.8 | 6-11 | ||
|
| ||||
| 4 | Duration of goitre (months) | 30.1 ± 32.6 | 60.5 ± 102.4 | 0.03 |
| Range (months) | 1-144 | 2-480 | ||
|
| ||||
| 5 | Clinical diagnosis |
|
| |
| STN | 46 | 19 | ||
| MNG-both lobes | 11 | 14 | ||
| MNG-one lobe | 1 | 1 | ||
| AFTN | 1 | 0 | ||
| Graves' disease | 0 | 1 | ||
| Toxic MNG | 0 | 4 | ||
| Postoperative histology of differentiated thyroid carcinoma (DTC) | 2 | 1 | ||
|
| ||||
| 7 | Preoperative FNAC | |||
| Not done | 3 | 1 | ||
| Bethesda I | 1 | 1 | ||
| Bethesda II | 44 | 30 | ||
| Bethesda III | 3 | 3 | ||
| Bethesda IV | 6 | 4 | ||
| Bethesda V | 1 | 1 | ||
| Bethesda VI | 3 | 0 | ||
Details of operative procedure, operation time, and perioperative outcomes.
|
|
|
|
|
|
|---|---|---|---|---|
| 1 | Approach - ABA | 30 (49.2%) | 9 (22.5%) | 0.07 |
| - BABA | 31 (50.8%) | 31 (77.5%) | ||
|
| ||||
| 2 | Surgery performed | |||
| TT | 12 | 19 | ||
| HT | 43 | 20 | ||
| CT | 3 | 1 | ||
| TT+CCND | 2 | 0 | ||
| TT+CCND+SLND | 1 | 0 | ||
|
| ||||
| 3 | Conversion to open | 1 | 3 | 0.13 |
|
| ||||
| 4 | Mean gland weight (grams) | 21.5 ± 15.3 | 62.3 ± 51.3 | 0.001 |
| Range (grams) | 6-60 | 18-253 | ||
|
| ||||
| 5 | Mean Operation time | |||
| Hemithyroidectomy (mins) | 152.0 ± 38.6 | 184.3 ± 85.5 | 0.15 | |
| Total Thyroidectomy (mins) | 206.4 ± 62.0 | 243 ± 57.92 | 0.22 | |
| TT+CCND | 220 + 28.3 | - | ||
| Completion Thyroidectomy (mins) | 96.5 ± 23.3 | 145 | 0.33 | |
|
| ||||
| 6 | Mean hospital stay (days) | 3.4 ± 1.4 | 4.1 ± 1.2 | 0.01 |
|
| ||||
| 7 | Complications | |||
| Transient RLN palsy | 4 (6.5%) | 2 (5%) | 0.11 | |
| Transient hypocalcaemia¥ (Biochemical/Clinical) | 7/18(38.9%) | 11/20(55.0%) | 0.51 | |
| Permanent RLN palsy | 1(1.6%) | 0 | 1.0 | |
| Permanent hypoparathyroidism¥ | 0 | 0 | ||
| Seroma | 2.1 ± 0.1 | 2.0 | 1.0 | |
| Skin bruising/hematoma | 2.3 ± 2.6 | 2.0 ± | 1.0 | |
| Paraesthesia | 2.1 ± 0.2 | 2.0 ± | 0.51 | |
∗: p value <0.05 was considered significant.
¥: transient hypocalcaemia and permanent hypoparathyroidism were calculated only for patients who underwent CT, TT, or TT+CCND±SLND.
Details of final histopathology.
|
|
|
|
|---|---|---|
| Benign (Colloid/MNG/Follicular adenoma) | 50 | 30 |
| Lymphocytic thyroiditis | 2 | 3 |
| Classical PTC | 3 | 1 |
| FVPTC | 1 | 1 |
| MIFTC | 1 | 2 |
| WIFTC | 1 | 0 |
| HCC | 0 | 1 |
| Primary hyperplasia | 0 | 1 |
| No evidence of malignancy | 3 | 1 |
MNG: multinodular goitre; PTC: papillary thyroid carcinoma; FVPTC: follicular variant of PTC; MIFTC: minimally invasive follicular thyroid carcinoma; WIFTC: widely invasive FTC; HCC: Hurthle cell carcinoma.